ArticleJournal of clinical immunology2010
Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus.
Article in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Evaluating Dickkopf-1 as a biomarker: insights into periodontitis, rheumatoid arthritis, and their comorbidity-a systematic review and meta-analysis.Frontiers in dental medicine · 2025Pooled it
- Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2017Pooled it
- Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis.Experimental & molecular medicine · 2016Pooled it
- Increased Prevalence of Autoimmune Rheumatologic Diseases in Patients With Primary Hyperparathyroidism.Cureus · 2023Article
- MRL/MpJ Mice Resist to Age-Related and Long-Term Ovariectomy-Induced Bone Loss: Implications for Bone Regeneration and Repair.International journal of molecular sciences · 2023Article
- Fufang shenhua tablet, astragali radix and its active component astragaloside IV: Research progress on anti-inflammatory and immunomodulatory mechanisms in the kidney.Frontiers in pharmacology · 2023Review
- The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.Frontiers in endocrinology · 2021Review
- Dickkopf-1 Is a Biomarker for Systemic Lupus Erythematosus and Active Lupus Nephritis.Journal of immunology research · 2017Article
- Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases.Journal of immunology research · 2016Review
- Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Paget's disease of bone: an osteoimmunological disorder?Drug design, development and therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to explore the potential role of circulating Dickkopf-1 (Dkk-1) and osteoprotegerin (OPG) in evaluating erosive arthritis in systemic lupus erythematosus (SLE).
methodsSerum Dkk-1 and OPG levels were examined in 130 SLE patients including eight with erosive arthritis, 100 rheumatoid arthritis (RA) patients and 50 healthy individuals by ELISA. Comparison of serum Dkk-1 levels with presence of anti-cyclic citrullinated peptides (CCP) antibodies in evaluating erosive arthritis in SLE was carried out. Associations of Dkk-1 and OPG levels with results of clinical examination were also noted.
resultsDkk-1 levels were significantly increased in eight SLE patients with erosive arthritis, compared to 58 SLE patients with non-erosive arthritis, 64 SLE patients without arthritis, and healthy controls, while similar with RA. In contrast, no significant changes of OPG levels were found except for higher levels in RA. No differences were found in Dkk-1 levels of SLE patients with erosive arthritis subdivided according to presence or absence of anti-CCP antibodies. Moreover, higher levels of Dkk-1 were identified in anti-CCP positive SLE patients with erosive arthritis compared to those with non-erosive arthritis or without arthritis. However, no significant correlations between Dkk-1 and OPG levels or between Dkk-1 levels and other laboratory and clinical manifestations were observed.
conclusionsHigh levels of circulating Dkk-1 were associated with bone erosion in patients with SLE, even when anti-CCP antibodies were absent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.